Cargando…

CRISPR/Cas9 delivery by NIR-responsive biomimetic nanoparticles for targeted HBV therapy

BACKGROUND: Currently, there are no curative drugs for hepatitis B virus (HBV). Complete elimination of HBV covalently closed circular DNA (cccDNA) is key to the complete cure of hepatitis B virus infection. The CRISPR/Cas9 system can directly destroy HBV cccDNA. However, a CRISPR/Cas9 delivery syst...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Dan, Chen, Ling, Li, Chengbi, Long, Quanxin, Yang, Qing, Huang, Ailong, Tang, Hua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740473/ https://www.ncbi.nlm.nih.gov/pubmed/34991617 http://dx.doi.org/10.1186/s12951-021-01233-4

Ejemplares similares

Application of CRISPR/Cas9 Technology to HBV
por: Lin, Guigao, et al.
Publicado: (2015)

The Advance of CRISPR-Cas9-Based and NIR/CRISPR-Cas9-Based Imaging System
por: Qiao, Huanhuan, et al.
Publicado: (2021)

Nanoparticle Delivery of CRISPR/Cas9 for Genome Editing
por: Duan, Li, et al.
Publicado: (2021)

Inhibition of HBV Expression in HBV Transgenic Mice Using AAV-Delivered CRISPR-SaCas9
por: Li, Hao, et al.
Publicado: (2018)

The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo
por: Lin, Su-Ru, et al.
Publicado: (2014)

Complete Spectrum of CRISPR/Cas9-induced Mutations on HBV cccDNA
por: Seeger, Christoph, et al.
Publicado: (2016)

Lipid-Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Components
por: Kazemian, Pardis, et al.
Publicado: (2022)

DHX9 interacts with APOBEC3B and attenuates the anti-HBV effect of APOBEC3B
por: Chen, Yanmeng, et al.
Publicado: (2020)

Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR/Cas9 genome editing
por: Zhang, Song, et al.
Publicado: (2021)

OMRT-12. Nanoparticle-based CRISPR-Cas9 delivery for anti-glioblastoma immunotherapy
por: Aguilar, Rocio, et al.
Publicado: (2021)

Robust genome editing in adult vascular endothelium by nanoparticle delivery of CRISPR-Cas9 plasmid DNA
por: Zhang, Xianming, et al.
Publicado: (2022)

Recent Advances in CRISPR/Cas9 Delivery Strategies
por: Yip, Bon Ham
Publicado: (2020)

Editorial: Current approaches to CRISPR/Cas9 delivery
por: Uludağ, Hasan, et al.
Publicado: (2022)

Permanent Inactivation of HBV Genomes by CRISPR/Cas9-Mediated Non-cleavage Base Editing
por: Yang, Yu-Chan, et al.
Publicado: (2020)

Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing
por: Wei, Tuo, et al.
Publicado: (2020)

Recent Progress and Future Prospective in HBV Cure by CRISPR/Cas
por: Yang, Yu-Chan, et al.
Publicado: (2021)

In vivo delivery of CRISPR-Cas9 therapeutics: Progress and challenges
por: Behr, Matthew, et al.
Publicado: (2021)

Advances in Chitosan-Based CRISPR/Cas9 Delivery Systems
por: Caprifico, Anna E., et al.
Publicado: (2022)

CRISPR-Cas9 delivery strategies with engineered extracellular vesicles
por: Lu, Yaoyao, et al.
Publicado: (2023)

BSA-PEI Nanoparticle Mediated Efficient Delivery of CRISPR/Cas9 into MDA-MB-231 Cells
por: Rahimi, Hossein, et al.
Publicado: (2022)

Delivery of CRISPR/Cas9 Plasmid DNA by Hyperbranched Polymeric Nanoparticles Enables Efficient Gene Editing
por: Xiu, Kemao, et al.
Publicado: (2022)

Patients with SARS-CoV-2 and HBV co-infection are at risk of greater liver injury
por: Lin, Yong, et al.
Publicado: (2020)

CRISPR/Cas12-Based Ultra-Sensitive and Specific Point-of-Care Detection of HBV
por: Ding, Ronghua, et al.
Publicado: (2021)

How Type II CRISPR-Cas establish immunity through Cas1-Cas2 mediated spacer integration
por: Xiao, Yibei, et al.
Publicado: (2017)

VSV-G-Enveloped Vesicles for Traceless Delivery of CRISPR-Cas9
por: Montagna, Claudia, et al.
Publicado: (2018)

Delivery systems of CRISPR/Cas9-based cancer gene therapy
por: Biagioni, Alessio, et al.
Publicado: (2018)

CRISPR/Cas9: Principle, Applications, and Delivery through Extracellular Vesicles
por: Horodecka, Katarzyna, et al.
Publicado: (2021)

Lower Mutation Frequency of BCP/Precore Regions in e Antigen-Negative Chronic HBV-Infected Children instead of Adults Patients
por: Huang, Yong, et al.
Publicado: (2015)

What is CRISPR/Cas9?
por: Redman, Melody, et al.
Publicado: (2016)

Advances in CRISPR/Cas9
por: Zhu, Youmin
Publicado: (2022)

Multistage Delivery Nanoparticle Facilitates Efficient CRISPR/dCas9 Activation and Tumor Growth Suppression In Vivo
por: Liu, Qi, et al.
Publicado: (2018)

Lipid-coated mesoporous silica nanoparticles for anti-viral applications via delivery of CRISPR-Cas9 ribonucleoproteins
por: LaBauve, Annette E., et al.
Publicado: (2023)

Application of CRISPR/Cas9 for biomedical discoveries
por: Riordan, Sean M., et al.
Publicado: (2015)

DNA nanomapping using CRISPR-Cas9 as a programmable nanoparticle
por: Mikheikin, Andrey, et al.
Publicado: (2017)

A Highly Sensitive and Specific Detection Method for Mycobacterium tuberculosis Fluoroquinolone Resistance Mutations Utilizing the CRISPR-Cas13a System
por: Bai, Xiaopeng, et al.
Publicado: (2022)

CRISPR/Cas9‐mediated knockout of HBsAg inhibits proliferation and tumorigenicity of HBV‐positive hepatocellular carcinoma cells
por: Song, Jia, et al.
Publicado: (2018)

Pacbio Sequencing of PLC/PRF/5 Cell Line and Clearance of HBV Integration Through CRISPR/Cas-9 System
por: Chen, Chia-Chen, et al.
Publicado: (2021)

CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy
por: Rosenblum, Daniel, et al.
Publicado: (2020)

Real-time Observation of CRISPR spacer acquisition by Cas1–Cas2 integrase
por: Budhathoki, Jagat B., et al.
Publicado: (2020)

CRISPR-Cas9 delivery to hard-to-transfect cells via membrane deformation
por: Han, Xin, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_9p66ggmmnaihpkfdficst50o79